Epigallocatechin-3-gallate (EGCG), the principal catechin of green tea, modulates different molecular mechanisms underlying hepatocellular carcinoma (HCC). Accumulating studies showed that the activation of prostaglandin (PG) receptor EP 1 promotes cell migration and invasion in different cancers, which could be inverted by blocking the EP 1 receptor. This study investigated the synergetic effects of EP 1 -selective antagonist ONO-8711 and EGCG treatment on HCC to better understand the potential strategy to treat HCC. We found that EGCG significantly inhibited PGE 2 and EP 1 -selective agonist induced migration of HCC cells and increased the ratio of Bax/Bcl-2 even in the presence of ONO-DI-004 or PGE 2 . ONO-8711 significantly inhibited PGE 2 -induced HCC proliferation while increased the inhibitory effect of EGCG on HCC cell viability and migration ability compared with EGCG alone. These findings suggest that a combination of ONO-8711 and EGCG is a potential treatment for HCC therapy.
Introduction
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Although chemotherapy and radiotherapy are considered the principal approaches for HCC treatment, many patients receive a variety of treatments, given variability in outcomes. Recently, accumulating evidence has shown that Epigallocatechin-3-gallate (EGCG), an abundant bioactive ingredient in green tea, has cancerchemopreventive effects [1, 2] . Particularly, EGCG, an antioxidant compound, induces apoptosis and inhibits tumor progression through its antioxidant and anti-inflammatory properties in several types of cancer [3, 4] , including HCC [5] . Also, EGCG inhibits tumor growth directly through cell-cycle arrest and inducing apoptosis, and various proteins involved such as nuclear factor-kappa B [2, 6] . It is crucial to note that the suppression of nuclear factor-kappa B activation reduces the expression of cyclooxygenase-2 (COX-2) and prostaglandin (PG)E 2 production [7] . PGE 2 is catalyzed by COX-2, and it plays a key role in the pathogenesis of cancer, which leads by chronic inflammation [8, 9] . As a critical lipid mediator, PGE 2 binds to 4 identified EP receptors (EP 1 , EP 2 , EP 3 , and EP 4 ) to DOI: 10.1159/000502076 exert its biological functions. PGE 2 /EP 1 signaling pathway enhances HCC adhesion and migration through increasing the expression of survivin by activating EGFR and phosphorylation of focal adhesion kinase [10, 11] . EGFR phosphorylation and cell invasiveness induced by PGE 2 were blocked after EP 1 receptor knockdown by siRNA, or by the EP 1 receptor antagonist ONO-8711 [12] . Pharmacological and genetic studies show the selective EP 1 inhibitor significantly reduced colon cancer development, indicating this receptor plays a role in colon carcinogenesis [13] . A research showed that long-term administration of ONO-8711 in rat diet reduced azoxymethane-induced colon cancer incidence, multiplicity and volume of colon carcinomas [14] . One study showed that treatment with ONO-8713 significantly decreased PGE 2 levels and acute UVB-induced inflammation in skin [15] . Thus, these findings suggest that EP 1 -selective antagonists seem to be promising candidates as chemotherapy alternatives, or supplements.
The anticancer mechanisms of EGCG in HCC are still not very clear. In our previous study, we found that both selective EP 1 agonist and PGE 2 significantly increased HCC cell growth and migration. In addition, EGCG suppressed EP 1 and PGE 2 expression, proliferation and migration that were induced by PGE 2 or EP 1 agonist [16] . Therefore, we hypothesize that a selective EP 1 receptor antagonist may increase the inhibitory effect of EGCG on HCC cell growth and migration. In the present study, we investigated the synergetic effects of ONO-8711 and EGCG on HCC cell migration and apoptosis to clarify a novel approach to HCC therapy.
Materials and Methods
Drugs EGCG was purchased from Sigma (St Louis, MO, USA). EP1receptor-antibody was obtained from Cayman Chemical, Ann Arbor, MI, USA. ONO-8711 and ONO-DI-004 were obtained from ONO Pharmaceutical Co, Osaka, Japan.
Cell Lines
HepG2 was purchased from Shanghai cell bank, Chinese Academy of Sciences. The cells were cultured in DMEM containing 10% fetal bovine serum (FBS) at 37 ° C in 5% CO2/95% air.
Cell Proliferation Measurement
Proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazoliumbromide (MTT) assay (EZ4U; Biomedica, Vienna, Austria). HepG2 cells in exponential growth phase were seeded in a 96-well plate at a density of 8,000 cells per well and incubated overnight in DMEM medium supplemented with 10% FBS. Twenty-four hours of starvation in serum-free DMEM before cells were treated with PGE2 (4 × 10 -6 M), ONO-8711 (210 nmol/L), ONO-DI-004 (400 nmol/L) or EGCG (12.5, 25, 50 , 100 μg/mL). After treatment, 20 μL MTT solution (5.0 mg/mL in PBS) was added to each well, and the plates were placed in 37 ° C for another 4 h. The formazan were dissolved in Dimethyl Sulfoxide (150.0 μL per well) and the plates were placed on a shaker at a low speed for 10 min at room temperature (RT). After that, the plates were read using a microplate reader (American Bio-Tek) at 490 nm. The inhibition of cell proliferation was calculated using the following formula: inhibition of cell proliferation (%) = (OD of the experimental samples -OD of blank control group)/(OD of the control -OD of blank control group) × 100% (n = 6, mean ± SD).
Transwell Filter Cell Migration Assay
The bottom of Boyden chambers is covered with polycarbonate filters with 8 μmol/L pore size (Costar, Bodenheim, Germany) were used as described previously [29] . The upper compartment was filled with serum-free DMEM cell suspension with a density of 5 × 10 5 cells/mL. DMEM medium containing 10% FBS was added to the lower compartment. After incubation for 12 h at 37 ° C, the film was collected and it was found that cells adhered to the lower surface were fixed, stained and counted. The experiment was repeated 3 times with consistent results.
Wound Healing Assay
Cells were cultured in a 6-well plate and indicated at 37 ° C until the cells were confluent. The yellow tip was used to scratch across the confluent cell layer to make a linear wound, and the cells were washed with PBS 3 times to remove dead cells. After that the cells were incubated with different compounds at 37 ° C for 24 h and the pictures of the defined wound spot were taken with a microscope at 0 and 24 h. The area of the wound in the microscopic images was measured using Image J software (National Institutes of Health, MD). The relative distance of wound closure (%) = (distance at 0 h-distance at 24 h)/relative distance of control × 100%.
Immunofluorescence Microscopy
The coverslips were coated with collagen (25 μg/mL) and placed on the bottom of dishes. HepG2 cells climbed to coverslips and then were treated with different drugs. After that cells on coverslips were fixed with 4% paraformaldehyde in PBS for 30 min and blocked with 5% goat serum (Invitrogen, USA) in PBST (PBS supply with 0.1% Tween 20) for 30 min at RT and indicated with primary EP1-receptor antibody 2 h. Cells were washed with PBST 4 times, 5 min each time, and followed by a secondary antibody indication for 1 h. And the cells were washed 4 times again and mounted in Fluoromount G (Southern Biotechnology, USA). The cells were observed and pictured by Fluorescence Inversion Microscope System (Olympus Corporation, Japan), and measured by fluorescence spectrophotometers.
Western-Blot Analysis
Cells collection after treating with PGE2 or ONO-DI-004 for 2 h with or without an hour pretreatment with EGCG (100 μg/mL), and extracted protein with RIPA lysis buffer (Beyotime, China) contain 1% PMSF and 1% protease inhibitor (Bestbio, China). Concentration of protein was determined by Lowry Protein Assay. Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) was added to lysates at a ratio of 1: 2, and then heated at 95 ° C for 10 min. membranes (Millipore, Bedford, MA, USA), followed by indicating with blocking buffer (5% nonfat dry milk in Tris-buffered saline contain 0.1% Tween 20) for 1 h. After that membranes were indicated with primary antibodies overnight at 4 ° C and then indicated with appropriate HRP-conjugated secondary antibody at RT for 1 h. Immune complexes were performed with Enhanced chemiluminescence system (Pierce, Rockford, IL, USA) using hydrogen peroxide and luminol as substrate.
Cell Cycle and Cell Apoptosis Assay
Apoptotic cell death was analyzed by DNA fragmentation and total DNA. Cells were treated with different compounds for 24 h. Cells (1 × 10 6 ) were collected and fixed with 70% ethanol at -20 ° C for 24 h and then centrifuged to remove supernatant; after that they were resuspended in 1 mL PBS containing RNase A (10 μg/ mL) and incubated at 37 ° C for 30 min. It was followed by staining with Propidium Iodide (PI, 40 μg/mL) for 30 min on ice, and then detected by Flow Cytometer with WinMDI software. Cells with subdiploid content were considered apoptotic.
Statistical Analysis
Statistical analysis was performed using SPSS 11.5. All experiments were repeated at least 3 times. The results were presented as mean ± SE. Differences among different groups were analyzed using the non-parametric Kruskal-Wallis test. p < 0.05 was statistically significant.
Results

EGCG Inhibited PGE 2 or ONO-DI-004 Induced Proliferation and Migration in HCC Cells
The anti-migratory effect of EGCG on PGE 2 or ONO-DI-004-induced migration in HepG2 cell was measured by Transwell assay. Results showed that EGCG inhibited HepG2 migration in the presence of PGE 2 in a dose-dependent manner. Moreover, decreased ONO-DI-004 induced migration was observed after EGCG treatment ( Fig. 1a-d) . Besides, to observe the antiproliferative effect of EGCG in HepG2, cells were treated with a variety of EGCG concentrations analyzed by MTT assay. We found that EGCG significantly reduced cell viability in HepG2 cells ( Fig. 1e ; p < 0.01).
EGCG Inhibited PGE 2 or ONO-DI-004 Induced Anti-Apoptosis Effect in HepG2 Cells
EGCG treatment inhibited cell contact and enhanced the presence of early apoptotic morphology such as rounding off and chromatin condensation ( Fig. 2a ). Furthermore, apoptosis was measured after treating with EGCG, PGE 2 or ONO-DI-004 in HepG2 cells via Flow Cytometer. As a result, PGE 2 or ONO-DI-004 significantly inhibited HepG2 cell apoptosis, which could be inverted by EGCG ( Fig. 2b) .
EGCG Increased the Ratio of Bax/Bcl-2 Inhibited by PGE 2 or ONO-DI-004 in HepG2 Cells
Next, we investigated the effects of EGCG on Bcl-2, Bax and caspase-3 expression to more clearly understand that how EGCG affects apoptosis via PGE 2 /EP 1 signaling. We found that Bcl-2 translation was significantly stimulated by PGE 2 or ONO-DI-004 in HepG2 cells (Fig. 3a) . To the opposite, the ratio of Bax/Bcl-2 was significantly increased after EGCG treatment (Fig. 3b ). In addition, caspase-3 expression was significantly lower after EGCG treatment compared with that of PGE 2 or ONO-DI-004 alone (Fig. 3c ).
EGCG Induced Cell Cycle Arrest in the Presence of PGE 2 and ONO-DI-004 in HepG2 Cells
The effect of EGCG, PGE 2 and ONO-DI-004 on cell cycle progression in HepG2 cells was detected by flow cytometry. Results showed that normal cell cycle progression was disrupted after PGE 2 and ONO-DI-004 treatment with more cells in S phase compared with control group. Nevertheless, the percentage of G2/M phase cells increased from 13.7 to 23.7% with EGCG treatment compared with control group. Besides, EGCG induced cell cycle arrest in the G2/M phase in the presence of either PGE 2 or ONO-DI-004 (Table 1 , p < 0.01).
The Combination of EGCG and ONO-8711 Inhibited Proliferation and Migration in HepG2 Cell
Here, we determined whether the EP 1 receptor plays a role in PGE 2 -induced HCC carcinogenesis by measuring the effects of EP 1 antagonist ONO-8711 on HepG2 cells in the presence of PGE 2 by MTT assay. Results showed that ONO-8711 inhibited PGE 2 -induced proliferation of HepG2 cells (Fig. 4a ). Furthermore, we designed to test effects of combination of EGCG and ONO-8711 on cell proliferation. Treatment with the combination of EGCG and ONO-8711 resulted in significantly additional inhibitory effects on HepG2 cells proliferation ( Fig. 4b ; p < 0.01). In addition, we investigated whether combination treatment had an additive effect on HCC cell migration measured by a wound healing assay. Results demonstrated that combination treatment had an additional effect on HepG2 cell migration compared with either treatment alone (Fig. 4c, d) .
The Combination of EGCG and ONO-8711 Reduced EP 1 Receptor Expression
We determined whether the expression of EP 1 receptor was altered after treating with EGCG and ONO-8711 DOI: 10.1159/000502076 detected by Immunofluorescence microscopy. First, we investigated the action of ONO-DI-004 on EP 1 expression at different time points. We found that the expression of EP 1 protein was remarkably increased at 2 h treated with ONO-DI-004 ( Fig. 5a ). Therefore, protein expression was detected at 2 h after treatment in the further test. Indeed, results showed EP 1 protein expression was significantly enhanced after treatment with PGE 2 or ONO-DI-004, but decreased in combination treatment of EGCG and ONO-8711 ( Fig. 5b, 
Discussion
The compounds in green tea mainly consist of epigallocatechin gallate (EGCG), caffeic acid, gallic acid, catechin (C), epicatechin (EC), gallocatechin (GC), epigallocatechin, C gallate, EC gallate, and GC gallate. EGCG is the major C in tea. One previous study demonstrated that the antiproliferative effects of GC, epigallocatechin, GC gallate, and EGCG were stronger than their corresponding compounds C, EC, C gallate, and EC gallate respectively [17] . Besides, EGCG is the most effective cancer chemopreventive polyphenol in green tea [17] .
The present study demonstrated that EGCG inhibited PGE 2 and ONO-DI-004 induced HCC migration and proliferation, as well as promoted HCC apoptosis. In addition, increased ratio of Bax/Bcl2 but decreased EP 1 protein expression was observed after EGCG treatment. Furthermore, the synergistic effect of EGCG and ONO-8711 showed in suppressing proliferation and migration of HCC cells.
Apoptosis, a form of programmed cell death, plays a crucial role in the maintenance of cellular and tissue homeostasis [18] . The proteins of the Bcl-2 family are essential regulators of apoptosis, such as Bcl-2 and Bax [19] . A previous study observed that EGCG induced [20] . In the current study, we found that EGCG induced apoptosis and down-regulated Bcl-2 and caspase-3 even in the presence of PGE 2 or EP 1 agonist in HepG2 cells. In addition, Bax protein was upregulated. These findings suggest that EGCG induces apoptosis by increasing the ratio of Bax/Bcl-2. The results are consistent with a previous research that showed caspase-3/7 activity decreased after EGCG treatment [21] . However, some data show caspase-3 activation after EGCG treatment [22] . The conflicting results may be explained by differing cell phase timing and cell lines. Further studies are needed to clarify these findings. Together, these results indicate that EGCG induce apoptosis in a variety of ways in HCC cells, but apoptosis of HepG2 cells was induced mainly by targeting Bcl-2 and upregulating Bax. The cell cycle is regulated precisely to avoid proliferation under adverse conditions. Cells are arrested in G1, S and G2/M phases to prevent replication of damaged DNA or aberrant mitosis. One recent study demonstrated that EGCG functionalized chitin derivative inhibited more HepG2 cells in the G2/M phase [23] . Consistently, in the current study, the result showed that cells were arrested in the G2/M phase by treating with EGCG in the presence of PGE 2 and ONO-DI-004 or not. However, another study observed that EGCG arrested SMMC7721 cells at S phase [24] . The conflict result might be attributed to the unique features of HCC cell lines.
Accumulating studies have showed that EP receptors are important in the development of other types of cancers, including colon and breast cancer, and they highlight that the specific EP receptor antagonists were effec-tive when they are used as chemopreventive agents [25, 26] . EGCG modulates a variety of molecular pathways in HCC, including inhibiting expression of COX-2 and mPGES [27, 28] . Our previous study showed that EGCG downregulated PGE 2 in HCC cells. Moreover, we found that the growth and migration of HCC cells in vitro were decreased after treating with ONO-8711 by blocking the EP 1 receptor [16] . In the current study, EGCG could suppress PGE 2 or ONO-DI-004 induced migration and antiapotosis. Moreover, synergetic anti-proliferative and anti-migratory effects of ONO-8711 and EGCG were observed. Those findings suggested that the regulation of PGE 2 -EP 1 signaling plays an important role in HCC. Clearly, the detailed mechanism is not understood, and more work is needed.
In conclusion, our study provides evidence that the combination of EGCG and EP 1 receptor antagonist inhibited HCC cell growth by affecting cell growth, migration, and cell cycle as well as inducing apoptosis via downregulation of PGE 2 /EP 1 activity. The results suggested that the combination of EGCG and EP 1 receptor antagonist might be a potential anticancer strategy in HCC therapy.
